New xenograft-based dressing might hit the market by summer

02/21/2012 | MedCityNews.com

Harbor Medtech is preparing to submit a request that the FDA approve its NeuvoCell wound dressing based on porcine tissue. NeuvoCell will be less expensive than similar products already on the market, requires applications only once or twice instead of every seven to 10 days, and will be appropriate to treat diabetic foot ulcers, pressure ulcers and burns, founder Jerry Mezger said.

View Full Article in:

MedCityNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Chief Executive Officer
UCare Minnesota
Minneapolis, MN